The severe hypertriglyceridemia market is expected to experience steady growth, driven by the rising prevalence of obesity, diabetes, metabolic syndrome, and other cardiometabolic disorders associated with elevated triglyceride levels. Additionally, the expected launch of emerging therapies such as Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), and others will further propel the market growth.

LAS VEGAS, Oct. 20, 2026 /PRNewswire/ -- Recently published Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, severe hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Severe Hypertriglyceridemia Market Summary

- The total severe hypertriglyceridemia treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest severe hypertriglyceridemia treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- The total number of diagnosed prevalent cases of SHTG in the 7MM were nearly 3.64 million cases in 2025 and is projected to increase during the forecast period.

- Leading severe hypertriglyceridemia companies, such as Arrowhead Pharmaceuticals, 89bio, Eli Lilly and Company, Ionis Pharmaceuticals, CRISPR Therapeutics, Northsea Therapeutics B.V., and others, are developing new severe hypertriglyceridemia treatment drugs that can be available in the severe hypertriglyceridemia market in the coming years.

- The promising severe hypertriglyceridemia therapies in clinical trials include Plozasiran (ARO-APOC3), Pegozafermin (BIO89-100), Solbinsiran (LY3561774), ION775, CTX310, SEFA-1024 (NST-1024), and others.

Discover the new therapeutic targets for severe hypertriglyceridemia @ https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market

Key Factors Driving the Growth of the Severe Hypertriglyceridemia Market

- Rising Prevalence of Metabolic Disorders: The increasing burden of obesity, type 2 diabetes, metabolic syndrome, and other cardiometabolic conditions is contributing to higher triglyceride levels. The growing prevalence of these risk factors is expected to expand the severe hypertriglyceridemia patient pool.

- Advances in RNA-Based Therapeutics: Progress in antisense oligonucleotide and other RNA-targeted technologies is enabling the development of therapies designed to directly regulate pathways involved in triglyceride metabolism. These innovations are broadening the treatment landscape for patients with severe hypertriglyceridemia.

- Emergence of Ionis' TRYNGOLZA: Ionis' TRYNGOLZA (olezarsen) approval is expected to strengthen the treatment landscape for severe hypertriglyceridemia (sHTG), providing a targeted therapeutic option for patients with markedly elevated triglyceride levels. Its approval may increase competition in a market historically characterized by limited disease-specific treatment options and reliance on triglyceride-lowering agents.

- Launch of Emerging SHTG Drugs: The dynamics of the SHTG market are expected to change in the coming years due to the launch of emerging therapies such as Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), CTX310 (CRISPR Therapeutics), SEFA-1024 (NST-1024; Northsea Therapeutics B.V.), and others.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that for Ionis, TRYNGOLZA approval is more than a new product launch; it's the company's first fully independent commercial rollout in a prevalent disease, a meaningful step up from its historical focus on rare conditions. With plozasiran's sHTG trials maturing and several other mechanisms in the wings, TRYNGOLZA's window of uncontested leadership may be measured in a few short years rather than a decade.

Severe Hypertriglyceridemia Market Analysis

- Treatment for severe hypertriglyceridemia typically includes dietary and lifestyle modifications alongside lipid-lowering therapies such as fibrates, omega-3 fatty acids, statins, and niacin. Among these therapies, statins currently account for the largest share of the market, followed by fibrates.

- Despite the availability of established treatments, including statins, fibrates, and omega-3 fatty acids, SHTG continues to substantially affect patients' quality of life, highlighting a significant unmet need for more effective therapeutic options.

- VASCEPA (icosapent ethyl) is FDA-approved for the treatment of SHTG and cardiovascular risk reduction. However, its triglyceride-lowering effect is relatively modest, and treatment is associated with risks such as atrial fibrillation and bleeding.

- In June 2026, the FDA approved Ionis' TRYNGOLZA as the first and only treatment indicated to reduce triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia. The approval for sHTG was supported by data from the Phase 3 CORE and CORE2 trials.

- The therapeutic landscape is also evolving with the development of novel treatment approaches across multiple molecular classes, including antisense oligonucleotides, small interfering RNA (siRNA), recombinant proteins, and small-molecule therapies.

- Leading companies such as Arrowhead Pharmaceuticals, with plozasiran; 89bio, with pegozafermin; and NorthSea Therapeutics, with SEFA-1024, among others, are actively evaluating their respective drug candidates.

Severe Hypertriglyceridemia Competitive Landscape

Some of the severe hypertriglyceridemia drugs under development include Plozasiran (ARO-APOC3; Arrowhead Pharmaceuticals), Pegozafermin (BIO89-100; 89bio), Solbinsiran (LY3561774; Eli Lilly and Company), ION775 (Ionis Pharmaceuticals), CTX310 (CRISPR Therapeutics), SEFA-1024 (NST-1024; Northsea Therapeutics B.V.), and others.

Arrowhead Pharmaceuticals' Plozasiran (formerly ARO-APOC3) is an investigational RNA interference (RNAi) therapy designed to reduce the production of apolipoprotein C-III (ApoC3) through the endogenous RNAi pathway. ApoC3 is produced primarily by liver cells and plays a role in regulating lipid and lipoprotein metabolism, including the production and clearance of triglyceride-rich particles.

89bio's Pegozafermin is an investigational fibroblast growth factor 21 (FGF21) analog developed using glycoPEGylation technology and site-specific mutations to replicate key biological activities of native FGF21 while extending its half-life. By targeting underlying metabolic dysfunction, pegozafermin has the potential to address liver and cardiometabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

Ionis' ION775 is an investigational apolipoprotein C-III (apoC-III) small interfering RNA (siRNA) therapy being evaluated in patients with severe hypertriglyceridemia (sHTG). The therapy is designed to provide durable apoC-III suppression, with the potential to support a twice-yearly dosing regimen. ION775 represents Ionis' first siRNA medicine to enter clinical development.

Northsea Therapeutics' SEFA-1024 is an oral, gut- and liver-targeted, semi-synthetic eicosapentaenoic acid (EPA) derivative under development for the treatment of severe hypertriglyceridemia (sHTG). The condition is associated with a substantially elevated risk of acute pancreatitis and may also contribute to increased cardiovascular event risk. Significant unmet need remains due to the limited efficacy of currently available therapies in reducing triglycerides (TG) and non-HDL cholesterol while improving glycemic control. Supported by extensive preclinical data from a translatable human hypertriglyceridemia model, SEFA-1024 may have the potential to address some of the limitations associated with current sHTG treatment approaches.

The anticipated launch of these emerging therapies are poised to transform the severe hypertriglyceridemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the severe hypertriglyceridemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the severe hypertriglyceridemia treatment market @ Severe Hypertriglyceridemia Drugs

Recent Developments in the Severe Hypertriglyceridemia Market

- In August 2026, Arrowhead Pharmaceuticals, Inc. presented findings from the pivotal Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia (sHTG) at the Hot Line Late-Breaking Science session during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.

- In August 2026, Ionis Pharmaceuticals, Inc. presented the new data on the management of severe hypertriglyceridemia (sHTG) at the 2026 European Society of Cardiology (ESC) Congress, scheduled to take place from August 28–31 in Munich.

- In August 2026, Arrowhead Pharmaceuticals, Inc. announced that it has entered into an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). Arrowhead plans to use the PRV in connection with its anticipated Supplemental New Drug Application (sNDA) for plozasiran, which is expected to be submitted by the end of 2026. The application will seek to expand plozasiran's approved indication to include patients with severe hypertriglyceridemia (sHTG).

- In June 2026, Ionis Pharmaceuticals announced that the U.S.